U.S. Markets close in 2 hrs 42 mins
  • S&P 500

    4,300.17
    -97.77 (-2.22%)
     
  • Dow 30

    33,597.17
    -668.20 (-1.95%)
     
  • Nasdaq

    13,451.37
    -317.55 (-2.31%)
     
  • Russell 2000

    1,987.92
    -36.12 (-1.78%)
     
  • Crude Oil

    0 (0)
     
  • Gold

    1,836.10
    -6.50 (-0.35%)
     
  • Silver

    24.34
    -0.37 (-1.50%)
     
  • EUR/USD

    1.1348
    +0.0031 (+0.2724%)
     
  • 10-Yr Bond

    1.7210
    -0.0260 (-1.49%)
     
  • Vix

    28.85
    +3.26 (+12.74%)
     
  • GBP/USD

    1.3555
    -0.0045 (-0.3321%)
     
  • USD/JPY

    113.6500
    -0.4500 (-0.3944%)
     
  • BTC-USD

    35,869.24
    +577.88 (+1.64%)
     
  • CMC Crypto 200

    813.42
    +2.81 (+0.35%)
     
  • FTSE 100

    7,494.13
    -90.88 (-1.20%)
     
  • Nikkei 225

    27,522.26
    -250.64 (-0.90%)
     

Recap: Omeros Q4 Earnings

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • OMER

Shares of Omeros (NASDAQ:OMER) fell in after-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share decreased 3.45% over the past year to ($0.60), which beat the estimate of ($0.64).

Revenue of $10,632,000 decreased by 68.18% from the same period last year, which missed the estimate of $14,910,000.

Guidance

Earnings guidance hasn't been issued by the company for now.

Omeros hasn't issued any revenue guidance for the time being.

Conference Call Details

Date: Mar 01, 2021

View more earnings on OMER

Time: 04:30 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/zwyuoz5o

Recent Stock Performance

Company's 52-week high was at $25.46

52-week low: $8.50

Price action over last quarter: Up 75.18%

Company Profile

Omeros Corp is a United States-based biopharmaceutical company. Its goal is to research, develop, and commercialize small-molecule and protein therapeutics targeting inflammation, coagulopathies, and disorders of the central nervous system. The company owns Omidria (phenylephrine and ketorolac injection), approved by the U.S. Food and Drug Administration and launched in the U.S. for use during cataract surgery and intraocular lens replacement. Its product pipeline is focused on complement-associated thrombotic microangiopathies; complement-mediated glomerulonephropathies; Huntington's disease and cognitive impairment; and addictive and compulsive disorders.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.